ReGen says Colostrinin may reduce cell mutation in cancer, aging

By Lisa Kerner

Charlotte, N.C., Aug. 25 - ReGen Therapeutics plc said results from a study in both hamster and human cells show that the company's Colostrinin compound may impact the aging process and cancer development, in addition to its known therapeutic effects in Alzheimer's disease.

Specifically, the results of the in-vitro study show that Colostrinin reduces the spontaneous or induced mutation frequency in the DNA of cells, according to a company news release.

Colostrinin reduced the frequency of mutation induced by reactive oxygen species in a dose-dependent manner. It also reduced the frequency of mutation caused by methyl methane sulphonate and mitomycin-C.

ReGen said its compound decreased UVA and UVB radiation-induced mutation frequency linked to malignant melanoma and squamous cell carcinomas.

The study, conducted at the University of Texas Medical Branch was published in the Journal of Experimental Therapeutics and Oncology.

Earlier this year, ReGen entered into an exclusive license agreement with California-based Metagenics, Inc. to commercialize Colostrinin as a human nutraceutical in North America.

ReGen is a London-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.